Recruiting studies: Monoclonal Antibody

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS
Phase 1 · 2 location(s) · HTIC, Inc · NCT07449572 Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Pat
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07128381 Predictive Signature of Benralizumab Response
Phase 4 · 20 location(s) · Nantes University Hospital · NCT04565483 Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Phase 3 · 116 location(s) · The Lymphoma Academic Research Organisation · NCT06284122 Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment
NA · 1 location(s) · Shanghai Zhongshan Hospital · NCT06794073 EWALL-PH OBSERVARTORY 2022
Phase N/A · 23 location(s) · Versailles Hospital · NCT07684131 A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination Wi
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07459751 A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in F
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07343089 FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Phase 1 · 5 location(s) · Pfizer · NCT06564389 Phase 1 Study of Intravaginal KB15A
Phase 1 · 1 location(s) · ZabBio Inc. · NCT07222020 BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826 Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
Phase 1/Phase 2 · 9 location(s) · Eledon Pharmaceuticals · NCT05027906 A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06437509 Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab a
Phase 2 · 1 location(s) · Dechang Diao · NCT07005570 Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07296627 Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06839560 A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Part
Phase 1 · 42 location(s) · Regeneron Pharmaceuticals · NCT05137054 Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07448779 An Outcome Analysis of Primary Membranous Nephropathy
Phase N/A · 2 location(s) · Mario Negri Institute for Pharmacological Research · NCT06242327 Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leu
Phase 3 · 460 location(s) · Alliance for Clinical Trials in Oncology · NCT03150693 Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
Phase N/A · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT05392413 Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant R
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT06259721 Residual Exacerbations With Mepolizumab
Phase N/A · 1 location(s) · Laval University · NCT04578171 Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
Phase N/A · 1 location(s) · Tongji Hospital · NCT06885957 A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
Phase 1 · 1 location(s) · CSL Behring · NCT07619820 A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Benefi
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT07111520 A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Phase 3 · 1 location(s) · Beijing Mabworks Biotech Co., Ltd. · NCT07405970 Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study)
Phase 1 · 1 location(s) · Aarhus University Hospital · NCT06668727 Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanom
Phase 1 · 2 location(s) · Yana Najjar · NCT04572451

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.